We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put EPIRUS Biopharmaceuticals's financial performance into perspective.
May 9, 2016
EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars to Treat Rare Diseases and Key Leadership Changes
Mar 15, 2016
EPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 Financial Results and Provides Business Update
Mar 15, 2016 at 8:00 AM ET
Feb 12, 2016 at 1:30 PM ET